Printer Friendly

Zavante Therapeutics signs clinical trial contract with National Institute of Allergy and Infectious Disease.

M2 PHARMA-September 11, 2017-Zavante Therapeutics signs clinical trial contract with National Institute of Allergy and Infectious Disease

(C)2017 M2 COMMUNICATIONS

Zavante Therapeutics Inc, a US-based biopharmaceutical company, has signed a clinical trial contract with the National Institute of Allergy and Infectious Disease (NIAID).

It was reported on Friday that the agreement has been signed to assess Zavante's investigational antibiotic, ZOLYD (fosfomycin for injection, also known as ZTI-01).

The clinical trial is designed to evaluate the intrapulmonary penetration and pharmacokinetics of ZOLYD to support future development as a treatment for United States patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonial infections. The US Food and Drug Administration has granted Fast Track and Qualified Infectious Disease Product designations to ZOLYD for both indications.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 11, 2017
Words:134
Previous Article:Pharming Group NV concludes End-of-Phase 2 interactions with the US FDA for the expanded use of RUCONEST in HAE patients.
Next Article:Genesis CancerCare Queensland uses the Venezia Brachytherapy Applicator in patients with advanced cervical cancer for the first time.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters